Analytical Data
-
Gene name
LY86
- Application
-
Alternative Names
LY86;MD1;Lymphocyte antigen 86
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O95711
-
Expression Region
21-162aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSGGGGKAW PTHVVCSDSG LEVLYQSCDP LQDFGFSVEK CSKQLKSNIN IRFGIILRED IKELFLDLAL MSQGSSVLNF SYPICEAALP KFSFCGRRKG EQIYYAGPVN NPEFTIPQGE YQVLLELYTE KRSTVACANA TIMCS
-
Molecular Weight
18 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LY86, also known as lymphocyte antigen 86, is a key protein involved in immune system regulation and has garnered considerable attention in research for its role in modulating both innate and adaptive immune responses. It functions primarily as a co-receptor that influences T cell activation and cytokine production, making it pivotal in various immune-related diseases, including autoimmune disorders and cancer. The study of LY86 has been propelled by its potential as a therapeutic target and a biomarker for disease progression. Recent advances in recombinant protein technology have enabled the production of LY86 in a laboratory setting, allowing for detailed analysis of its structural and functional properties. This research aims to elucidate the molecular mechanisms underlying its role in immune modulation, providing insights that could lead to innovative treatment strategies. Given the increasing prevalence of immune-related diseases, ongoing studies on LY86 not only enhance our understanding of immune regulation but also hold promise for developing novel immunotherapies.
